Biotechnology

Filter

Current filters:

None

Popular Filters

1960 to 1984 of 2516 results

Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate

19-11-2012

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with…

BioconBiotechnologyBristol-Myers SquibbDiabetesIN-105LicensingPharmaceuticalResearch

Geron signs tentative deal with BioTime on stem cell assets

18-11-2012

A year after announcing its decision to exit stem cell therapy, the USA's Geron Corp (Nasdaq: GERN) has…

BiotechnologyBioTimeFinancialGeron CorpMergers & Acquisitions

Merck & Co and Gilead highlight new data at international HIV meeting

16-11-2012

US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

Janssen starts new trial investigator databank, joined by Merck & Co and Lilly

15-11-2012

Janssen Research & Development, a unit of health care giant Johnson & Johnson (NYSE: JNJ) yesterday announced…

BiotechnologyPharmaceuticalResearchTransCelerate BioPharma

Rheumatoid arthritis researchers limber up, says GlobalData

15-11-2012

Upcoming therapeutics and an emerging biosimilars industry will improve the lives of Rheumatoid Arthritis…

Anti-Arthritics/RheumaticsBiotechnologyMarkets & MarketingPharmaceuticalResearch

YM BioSciences - to partner or not to partner?

13-11-2012

Canadian firm biotechnology firm YM BioSciences' (TSX: YM) conundrum of whether to partner or go it alone…

BiotechnologyCYT387FinancialLicensingResearchYM Biosciences

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Celgene's Abraxane meets primary endpoints in pancreatic cancer study

13-11-2012

In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm…

AbraxaneBiotechnologyCelgeneOncologyResearch

Incivo plus peginterferon and ribavirin positive for co-infected hep C and HIV patients, says Janssen

12-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Infectious Diseases - Diagnostics BVBA presented…

Anti-viralsBiotechnologyIncivoJanssenJohnson & JohnsonPharmaceuticalResearch

UK govt supports regenerative medicines, saying it is a priority area

11-11-2012

George Osborne, the UK's Chancellor of the Exchequer, spoke at the Royal Society last Friday of both…

BiotechnologyEuropeFinancialPharmaceuticalPoliticsRegulation

AMD and DR drug market will reach $6.25 billion in 2015, predicts Visiongain

08-11-2012

Regeneron's 2011 launch of Eylea (aflibercept) has stimulated the market, proving to be one of the most…

BiotechnologyMarkets & MarketingOphthalmicsPharmaceuticalResearch

Vivus plummets as early sales of obesity drug Qsymia disappoint

08-11-2012

US biopharma company Vivus (Nasdaq: VVUS) saw its shares plunge 24% to $11.38, after reporting third-quarter…

BiotechnologyFinancialMetabolicsPharmaceutical

Brazilian generic industry review

07-11-2012

The Brazilian pharmaceutical market is growing rapidly into one of the largest pharma markets in the…

BiotechnologyGenericsMarkets & MarketingSouth America

"New" CDER Exclusivity Board focuses on clarity and consistency of exclusivity decisions

07-11-2012

The US Food and Drug Administration recently announced that the agency has established within the Center…

BiotechnologyLegalNorth AmericaPatentsPharmaceuticalRegulation

Strong mid-stage results for Amgen's cholesterol drug candidate AMG 145

07-11-2012

Global biotech leader Amgen (Nasdaq: AMGN) has announced positive results from the AMG 145 Phase II GAUSS…

AMG 145AmgenBiotechnologyCardio-vascularPfizerPharmaceuticalResearchRN316

Extraneous clinical data collection costs drug developers $4-$6 billion a year, says Tufts CSDD

06-11-2012

One out of every five procedures performed during later stage clinical trials collects extraneous data…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

1960 to 1984 of 2516 results

COMPANY SPOTLIGHT

Menarini

Back to top